These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17640780)

  • 1. Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.
    Hu MC; Jones T; Kenney RT; Barnard DL; Burt DS; Lowell GH
    Vaccine; 2007 Aug; 25(34):6334-40. PubMed ID: 17640780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
    Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
    Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice.
    Zhou Z; Post P; Chubet R; Holtz K; McPherson C; Petric M; Cox M
    Vaccine; 2006 Apr; 24(17):3624-31. PubMed ID: 16497416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
    Li J; Ulitzky L; Silberstein E; Taylor DR; Viscidi R
    Viral Immunol; 2013 Apr; 26(2):126-32. PubMed ID: 23573979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.
    Shim BS; Stadler K; Nguyen HH; Yun CH; Kim DW; Chang J; Czerkinsky C; Song MK
    Virol J; 2012 Sep; 9():215. PubMed ID: 22995185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice.
    Lee JS; Poo H; Han DP; Hong SP; Kim K; Cho MW; Kim E; Sung MH; Kim CJ
    J Virol; 2006 Apr; 80(8):4079-87. PubMed ID: 16571824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
    Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N
    Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protollin: a novel adjuvant for intranasal vaccines.
    Jones T; Cyr S; Allard F; Bellerose N; Lowell GH; Burt DS
    Vaccine; 2004 Sep; 22(27-28):3691-7. PubMed ID: 15315848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
    Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
    J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
    Du L; Zhao G; Chan CC; Li L; He Y; Zhou Y; Zheng BJ; Jiang S
    Viral Immunol; 2010 Apr; 23(2):211-9. PubMed ID: 20374001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.
    Qiu X; Hong C; Li Y; Bao W; Gao XM
    Microbiol Immunol; 2012 Aug; 56(8):554-61. PubMed ID: 22530918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
    Jones T; Adamovicz JJ; Cyr SL; Bolt CR; Bellerose N; Pitt LM; Lowell GH; Burt DS
    Vaccine; 2006 Mar; 24(10):1625-32. PubMed ID: 16243411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.